概述
The staff within the Gene Transfer, Targeting and Therapeutics Viral Vector Core provide expert consultation for the safe and effective use of viral vector technologies, and offer custom design and production services for multiple viral vector types. The Gene Transfer, Targeting and Therapeutics Viral Vector Core facilitates the use of these powerful research tools by Salk researchers and others across diverse fields of study such as systems neuroscience, stem cell biology, metabolism, aging, cancer biology and gene therapy.
The U.S. Bureau of Industry and Security has updated the Export Administration Regulations regarding rabies vectors. We are now able to distribute reagents that contain any portion of the rabies genome only to countries that are part of the Australia Group:
https://www.dfat.gov.au/publications/minisite/theaustraliagroupnet/site/en/participants.html
国家癌症研究所
The GT3 core is a designated Cancer Center Council (C3) core facility. Cancer Center members from participating C3 institutes receive shared resource rates.
为提交使用本核心服务或资源的稿件，请通过包含以下信息来致谢支持：
“This work was supported by the GT3 Core Facility of the Salk Institute with funding from NIH-NCI CCSG: P30 CA014195”. Please acknowledge core staff where appropriate and consider authorship inclusion when scientific contributions merit.
请将每篇由该核心提供的研究产生的出版物链接到您的MyNCBI账户。这将确保NIH的贡献在续期和延期申请中得到适当的承认。这是NIH的一项要求，必须作为我们提供稳定资助的核心资源一致性访问的一部分来满足。. 有关如何链接出版物的信息，请参见此处»
托里松树路10010号
拉霍亚，加州 92037
电话：(858) 453-4100
Our offices are located just North of the Salk Institute in the Sanford Consortium for Regenerative Medicine building.
Office Location
Room 1318
Lab Location
Room 1106
GT3 Core email: GT3@salk.edu
John Naughton
Director, Gene Transfer, Targeting and Therapeutics Viral Vector Core
(858) 453-4100 ext. 1891
jnaughton@salk.edu
